AZ reports detailed lung cancer data for Imfinzi, Tagrisso

After stumbling on a disappointing readout from the Phase III MYSTIC trial, AstraZeneca plc (LSE:AZN; NYSE:AZN) regained some footing in the lung cancer space over the weekend with presentations at the European Society for Medical Oncology meeting in Madrid. The pharma reported detailed data from two Phase III trials evaluating Imfinzi durvalumab and Tagrisso osimertinib (AZD9291), respectively, to treat non-small cell lung cancer (NSCLC).

In July, AZ said PD-L1 inhibitor Imfinzi missed the co-primary endpoint in MYSTIC of improving progression-free survival (PFS) in previously untreated stage IV NSCLC patients whose tumors express PD-L1 on 25% or more of their cancer cells. Data for the trial's other co-primary endpoint of overall survival (OS) are expected in 1H18 (see BioCentury Extra, July 27)...